The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index; 35 of the 93 sources its claims cite were checked for support.
Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
Open accessAbstract
Glucagon-like peptide-1 (GLP-1) is an incretin hormone mainly secreted from intestinal L cells in response to nutrient ingestion. GLP-1 has beneficial effects for glucose homeostasis by stimulating insulin secretion from pancreatic beta-cells, delaying gastric emptying, decreasing plasma glucagon, reducing food intake, and stimulating glucose disposal. Therefore, GLP-1-based therapies such as GLP-1 receptor agonists and inhibitors of dipeptidyl peptidase-4, which is a GLP-1 inactivating enzyme, have been developed for treatment of type 2 diabetes. In addition to glucose-lowering effects, emerging data suggests that GLP-1-based therapies also show anti-inflammatory effects in chronic inflammatory diseases including type 1 and 2 diabetes, atherosclerosis, neurodegenerative disorders, nonalcoholic steatohepatitis, diabetic nephropathy, asthma, and psoriasis. This review outlines the anti-inflammatory actions of GLP-1-based therapies on diseases associated with chronic inflammation in vivo and in vitro, and their molecular mechanisms of anti-inflammatory action.
Overview
CoChat Summary
## TL;DR
This review argues that GLP-1-based therapies have anti-inflammatory effects beyond glucose lowering, with evidence across diabetes, vascular disease, brain disorders, liver disease, nephropathy, and other inflammatory conditions. It summarizes in vitro, animal, and some human findings showing reductions in inflammatory cytokines, immune-cell infiltration, and related signaling pathways.
## Key findings
- In diabetes, GLP-1-based therapies reduced inflammatory mediators in islets and adipose tissue: liraglutide (100 nM) inhibited palmitate-induced TNF-α, IL-1β, and IL-6 in mouse islets; sitagliptin (100 mg/day) reduced plasma CRP, IL-6, IL-18, secreted phospholipase-A2, soluble ICAM-1, and E-selectin in type 2 diabetes patients, while the inflammatory score and HOMA index for insulin resistance were also significantly reduced.
- In vascular disease, liraglutide reduced adhesion molecules in endothelial cells and exendin-4 reduced atherosclerosis in mice; for example, exendin-4 (50 μg/kg/day) reduced atherosclerosis development and monocyte adhesion in APOE*3-Leiden.CETP mice, and sitagliptin reduced plaque macrophage infiltration and MMP-9 in ApoE−/− mice.
- In neurodegenerative disease models, liraglutide reduced activated microglia and inflammatory responses in Alzheimer’s disease models, and exendin-4 (10 μg/kg) decreased MPTP-induced microglial activation and TNF-α/IL-1β in Parkinson’s disease models.
- In other conditions, liraglutide improved asthma-related inflammation (including lower E-selectin, TNF-α, IL-4, IL-5, and IL-13) and exenatide improved sperm quality in diet-induced obese mice by suppressing testicular TNF-α, MCP-1, and F4/80.
## Methods
- Narrative review of published in vivo and in vitro studies on GLP-1, GLP-1 receptor agonists, and DPP-4 inhibitors across inflammatory diseases.
- Evidence base includes cell models, rodent and other animal models, and selected human studies (for example, patients with type 2 diabetes and nonalcoholic steatohepatitis).
- Main analysis was qualitative synthesis of anti-inflammatory effects and molecular mechanisms, organized by disease area and signaling pathways.
## Limitations
- The paper states that some reported benefits “need to be validated by clinical studies” for asthma, and that the safety of GLP-1-based therapy should be validated by “sufficient further studies” because rare cases of acute pancreatitis and neoplasms have been reported.
- Evident from the text: this is a review, so many conclusions are based on preclinical or small clinical studies rather than a single controlled synthesis or meta-analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
26 Valid · 0 Not valid · 23 Not checked · 23 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Inflammation can be a mediator of insulin resistance and beta-cell damage by high glucose, fatty acids, or adipokines released from adipose tissues [37–39].”
§ Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control > 2. Diabetes
What the sources say
- Partly supportedcites [37] sourceExperimental — accuracy not yet measured
The “Autoimmunity and inflammation” section (page not provided) says high glucose and free fatty acids induce islet inflammation that contributes to beta-cell impairment and apoptosis. The “Adipokines” section says some adipose-derived factors promote inflammation and beta-cell failure. The paper does not establish that inflammation mediates insulin resistance, so that part of the attributed claim is unsupported. (LLM, conf=0.84)
- Partly supportedcites [38] sourceExperimental — accuracy not yet measured
The “Metabolic and Oxidative Stress” passage links glucotoxicity and lipotoxicity to β-cell damage. The “Inflammation” passage describes local islet inflammation in type 2 diabetes and says anti-inflammatory treatment can preserve some β-cell functional mass. Our copy does not establish that inflammation mediates insulin resistance or damage caused by adipose-derived adipokines, and it leaves the origin of islet inflammation unresolved. The indexed passages provide no page numbers. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [39] source
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Therefore, suppression of CXCL10 production by exendin-4 could reduce islet inflammation by decreasing cytotoxic T lymphocyte recruitment into the islets in autoimmune type 1 diabetes [48].”
§ Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control > 2. Diabetes
What the sources say
- Supportedcites [48] source
The paper's own Results ("Suppression of IFN-γ-induced CXCR3-binding chemokines by exendin-4 and cyclic AMP in human islets") show exendin-4 suppressing CXCL10 mRNA (~30% with rolipram, modest but significant with exendin-4 alone) and protein (38%), with reduced secretion into the medium, and the Introduction states that "CXCL10 plays an important role in trafficking effector T cells to islets during insulitis in type 1 diabetes" and that "suppression of CXCL10 production in islets could be an important therapeutic approach to reducing insulitis in type 1 diabetes." The citing sentence's hedged inference ("could reduce islet inflammation by decreasing ... T lymphocyte recruitment") reproduces that same reasoning, with "cytotoxic T lymphocyte" standing in for the source's CXCR3-bearing effector/activated T cells and NK cells. The source is in vitro human islets and MIN6 cells, so the type 1 diabetes benefit remains a stated possibility in both documents, not a demonstrated outcome. (LLM, conf=0.85)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Expression of the GLP-1 receptor is widely detected in various cells and organs including the kidney, lung, heart, hypothalamus, endothelial cells, neurons, astrocytes, and microglia as well as pancreatic beta-cells [12–17]”
§ Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control > 1. Introduction
What the sources say
- Partly supportedcites [12] sourceExperimental — accuracy not yet measured
The Results section (page unavailable) reports GLP-1 receptor expression in lung, pancreatic β-cells, and endothelial cells; the introductory text also refers broadly to neural cells. The paper does not establish receptor expression in the kidney, heart, hypothalamus, astrocytes, or microglia, nor does it identify neurons specifically. Its discussion of GLP-1 effects on the heart is not evidence of receptor expression there. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [13] source
- Not checked — no full text of the sourcecites [14] source
- Not checked — no full text of the sourcecites [15] source
- Not checked — no full text of the sourcecites [16] source
- Not checked — no full text of the sourcecites [17] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Thus, GLP-1 therapy may be beneficial for the treatment of chronic inflammatory diseases including nonalcoholic steatohepatitis, atherosclerosis, neurodegenerative disorders, diabetic nephropathy, asthma, and psoriasis [14, 26–32].”
§ Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [14] source
- Partly supportedcites [26] sourceExperimental — accuracy not yet measured
Vittone et al. (2012) supports only the atherosclerosis element of the list: the Discussion (p. 6) states that sitagliptin 'decreases plaque macrophage content and stabilises arteriosclerotic lesions in Apoe -/- mice, while GLP-1 directly inhibits monocyte migration and macrophage MMP-9 production in vitro', and the same passage notes broadly that 'there is evidence of anti-inflammatory effects of GLP-1 in different tissues'. Our copy makes no claim that GLP-1 therapy is beneficial in nonalcoholic steatohepatitis, diabetic nephropathy or asthma (searched: those terms plus 'chronic inflammatory diseases'); neurodegenerative and psoriatic disease appear only as titles of cited works (refs 25 and 26, References p. 9), not as conditions this paper shows GLP-1 treats. The remaining diseases in the citing list must rest on the other citations in the cluster [14, 26–31]. (LLM, conf=0.78)
- Not checked — no full text of the sourcecites [27] source
- Not checked — no full text of the sourcecites [28] source
- Not checked — no full text of the sourcecites [29] source
- Not checked — no full text of the sourcecites [30] source
- Partly supportedcites [31] sourceExperimental — accuracy not yet measured
The Conclusions/interpretation and Discussion (pages not provided) suggest therapeutic potential for GLP-1 in inflammatory conditions such as psoriasis, based on improvement observed in patients. The Discussion also mentions cardiovascular and neuroprotective effects, but the paper does not support the full list of proposed treatments, particularly nonalcoholic steatohepatitis, diabetic nephropathy, and asthma. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [32] source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“emerging data suggest that GLP-1-based therapies also showed anti-inflammatory effects on the liver, vascular system including aorta and vein endothelial cells, brain, kidney, lung, testis, and skin by reducing the production of inflammatory cytokines and infiltration of immune cells in the tissues [17, 21–25].”
§ Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [17] source
- Partly supportedcites [21] sourceExperimental — accuracy not yet measured
The GLP-1RAs AND INFLAMMATION section reports anti-inflammatory effects in endothelial cells and reduced inflammatory-cytokine release; the IL-6 and chemokines sections report reductions in the liver, brain, and kidney. The monocytes/macrophages section reports reduced macrophage infiltration in adipose tissue, not across the listed organs. The cited passages do not establish anti-inflammatory effects in the aorta, lung, testis, or skin. Page numbers were not available in our copy. (LLM, conf=0.88)
- Could not verifycites [22] sourceExperimental — accuracy not yet measured
Our copy of Blandino-Rosano et al. (2008) is confined to rat pancreatic islet/β-cell culture: the Abstract and the results section 'GLP-1 has a protective role against anti-proliferative effects of cytokines' show GLP-1 reversing IL-1β/IFN-γ/TNF-α-induced ERK1/2 inactivation and restoring β-cell proliferation, and the Discussion frames this as possible use in early-stage DM1. No passage addresses anti-inflammatory actions of GLP-1-based therapies in liver, aorta/vein endothelium, brain, kidney, lung, testis or skin, nor reduced cytokine production or immune-cell infiltration in those tissues (searched: extrapancreatic tissues/endothelial/kidney/anti-inflammatory in vivo; inflammatory cytokine production and immune infiltration). Since our copy neither states nor contradicts the tissue-level claim, it cannot be verified from this source. (LLM, conf=0.70)
- Partly supportedcites [23] sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked — no full text of the sourcecites [24] source
- Partly supportedcites [25] sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
47 more claims · 13 with their cited sources checked
Create a free account to see all 72 claims and to verify the 6 references still open.
- It may state two separate claims as one. 20
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1RAs have effects on systemic inflammation such as reduction in high-sensitivity C-reactive protein (hs-CRP) that are not mediated by weight loss or glycemic control [15, 27, 28].”
From evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease (2025) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There is increasing evidence that GLP-1RAs act as modulators of atherosclerosis, 76 and their anti-inflammatory and antioxidant properties may contribute to this, as supported by laboratory studies. 77,78”
The cited source says what the claim attributes to it.
In the citing paper
“Experimental and translational data support anti‐inflammatory and antioxidant actions of GLP‐1RAs beyond glycemic control [5].”
The cited source says what the claim attributes to it.
In the citing paper
“These benefits suggest important non‐glycemic effects, including modulation of inflammatory and vascular pathways [5].”
The cited source says what the claim attributes to it.
In the citing paper
“GLP‐1 receptor signalling may inhibit pro‐inflammatory transcriptional pathways, attenuate oxidative stress, improve endothelial function and modulate immune cell activation [5, 10].”
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“Nonalcoholic steatohepatitis [61, 93, 96]”
Cited work 10.1007/s00125-010-1831-8 · retracted 2011-12-15 · notice 10.1007/s00125-011-2394-z · this paper published 2016
Citations
Cites
1 retracted
Hattori, Y., Jojima, T., Tomizawa, A., Satoh, H., Hattori, S., Kasai, K., & Hayashi, T. (2010) · Diabetologia · doi:10.1007/s00125-010-1831-8 · Cited by 183 · cited 3×
“Nonalcoholic steatohepatitis [61, 93, 96]”
BackgroundRetractedRole of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Kanda, H. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26498 · Cited by 2,682
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · cited 1×
“GLP-1 has many beneficial effects on the control of blood glucose levels including stimulation of insulin secretion and inhibition of glucagon secretion, expansion of the beta-cell mass by stimulating beta-cell proliferation and differentiation and inhibiting beta-cell apoptosis, delay of gastric emptying, and reducti…”
BackgroundMicroglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism
Block, M. L., & Hong, J.-S. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.06.004 · Cited by 1,557
CCR2 modulates inflammatory and metabolic effects of high-fat feeding
Weisberg, S. P., Hunter, D., Huber, R., Lemieux, J., Slaymaker, S., Vaddi, K., Charo, I., Leibel, R. L., & Jr., A. W. F. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24335 · Cited by 1,497
Mechanisms of Pancreatic β-Cell Death in Type 1 and Type 2 Diabetes
Cnop, M., Welsh, N., Jonas, J.-C., Jörns, A., Lenzen, S., & Eizirik, D. L. (2005) · Diabetes · doi:10.2337/diabetes.54.suppl_2.s97 · Cited by 1,491
CCR2 modulates inflammatory and metabolic effects of high-fat feeding
Weisberg, S. P. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24335c1 · Cited by 1,425
Normalization of obesity-associated insulin resistance through immunotherapy
Winer, S., Chan, Y., Paltser, G., Truong, D., Tsui, H., Bahrami, J., Dorfman, R., Wang, Y., Zielenski, J., Mastronardi, F., et al. (2009) · Nature Medicine · doi:10.1038/nm.2001 · Cited by 1,370
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Cited by
COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Lim, S., Bae, J. H., Kwon, H.-S., & Nauck, M. A. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00435-4 · Cited by 1,006
Trends in insulin resistance: insights into mechanisms and therapeutic strategy
Li, M., Chi, X., Wang, Y., Setrerrahmane, S., Xie, W., & Xu, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01073-0 · Cited by 939
“These GLP-1 receptor agonists can suppress the inflammatory response of macrophages, thereby inhibiting IR.(469) (2) Dipeptidyl peptidase-4 (DPP-4) also referred as the T-cell antigen CD26 can degrade GLP-1.”
BackgroundResearch Progress on the Relationship between Atherosclerosis and Inflammation
Zhu, Y., Xian, X., Wang, Z., Bi, Y., Chen, Q., Han, X., Tang, D., & Chen, R. (2018) · Biomolecules · doi:10.3390/biom8030080 · Cited by 872
“Therefore, PLA2 inhibitors need to be studied in clinical trials [73].”
BackgroundVascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease
Steven, S., Frenis, K., Oelze, M., Kalinovic, S., Kuntic, M., Bayo Jimenez, M. T., Vujacic-Mirski, K., Helmstädter, J., Kröller-Schön, S., Münzel, T., et al. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/7092151 · Cited by 708
The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists
Bendotti, G., Montefusco, L., Lunati, M. E., Usuelli, V., Pastore, I., Lazzaroni, E., Assi, E., Seelam, A. J., El Essawy, B., Jang, J., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106320 · Cited by 406
Metadata
- Authors
- Lee, Y.-S., & Jun, H.-S.
- Affiliations
- Gachon University (KR)
- Corresponding author
- Jun, Hee-Sook
- Venue
- Mediators of Inflammation
- Publisher
- Wiley
- Published
- 2016
- Volume
- 2016
- Pages
- 1-11
- ISSN
- 0962-9351 (ISSN-L)
- 1466-1861
- PMC
- PMC4823510
- OpenAlex
- W2306319461
- Cited by
- 530
- References
- 116
- Citations by year
- 2026: 68 · 2025: 83 · 2024: 56 · 2023: 52 · 2022: 60 · 2021: 72 · 2020: 53 · 2019: 47 · 2018: 21 · 2017: 15 · 2016: 3
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Mediators of Inflammation (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Research Foundation of Korea (2015R1D1A1A01060232)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- glucagon-like peptide-1, GLP-1 receptor agonists, DPP-4 inhibitors, anti-inflammatory activity, chronic inflammation, type 2 diabetes, type 1 diabetes, atherosclerosis, neurodegenerative diseases, nonalcoholic steatohepatitis, diabetic nephropathy, asthma, psoriasis, glucose homeostasis, molecular mechanisms of inflammation
- MeSH terms
- Animals, Anti-Inflammatory Agents, Blood Glucose, Diabetes Mellitus, Type 2, Humans, Inflammation, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control. https://app.cochat.ai/papers/10.1155/2016/3094642
- The paper
- Lee, Y.-S., & Jun, H.-S. (2016). Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control. Mediators of Inflammation. https://doi.org/10.1155/2016/3094642
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.